Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer

BACKGROUND: The rationale for the evaluation of trametinib in advanced biliary cancer (BC) is based on the presence of mitogen-activated protein kinase alterations and on earlier promising results with MEK inhibitors in BC. METHODS: Patients with histologically proven BC who progressed on gemcitabin...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur J Cancer
Hlavní autoři: Kim, Richard D., McDonough, Shannon, El-Khoueiry, Anthony B., Bekaii-Saab, Tanios S., Stein, Stacey M., Sahai, Vaibhav, Keogh, George P., Kim, Edward J., Baron, Ari D., Siegel, Abby B., Barzi, Afsaneh, Guthrie, Katherine A., Javle, Milind, Hochster, Howard
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7539324/
https://ncbi.nlm.nih.gov/pubmed/32234665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2020.01.026
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky